To examine the relationship between adherence to antidepressant medications and HbA1c levels among patients with diabetes in a managed care setting.
Method:
The analysis included measures of HbA1c levels before, during, and after initial antidepressant use among 568 patients with diabetes enrolled in the Harvard Pilgrim Health Care insurance plan from 1991–1995. Adherence was defined as four refills in a six-month period after the first antidepressant prescription. General linear models using SAS PROC MIXED were used to estimate the effects of covariates including antidepressant adherence on HbA1c levels over time, comparing patients who were adherent to antidepressant medications to those patients who were non-adherent to antidepressant medications.
Results:
Adherence to antidepressant treatment was not significantly associated with HbA1c levels among diabetic patients who are antidepressant users. Younger age, use of insulin and oral medications, and female gender were all significantly associated with HbA1c levels over time.
Conclusions:
Although we did not observe any association between level of adherence to antidepressant therapy among diabetic patients and levels of glucose control, our results confirm previously established associations between patient characteristics and glycemic control. Further research is needed to disentangle the complex relationship among antidepressant treatment adherence and diabetes outcomes.
KesslerRC. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Archives of General Psychiatry1994; 51: 8–19.
2.
National Diabetes Data Group, National Institutes of Health, and National Institute of Diabetes and Digestive and Kidney Diseases, In: HarrisMI, editors. Diabetes in America (2nd ed.). Rockville, MD: NIH Publication No. 95-1468, 1995.
3.
AndersonRJ. The prevalence of comorbid depression in adults with diabetes: A meta-analysis. Diabetes Care2001; 24(6): 1069–1078.
4.
GavardJALustmanPJClouseRE. Prevalence of depression in adults with diabetes. An epidemiological evaluation. Diabetes Care1993; 16(8): 1167–1178.
GreenbergPE. Depression: A neglected major illness. Journal of Clinical Psychiatry1993; 54: 419–424.
7.
ContiDJBurtonWN. The economic impact of depression in a workplace. Journal of Occupational Medicine1994; 36(9): 983–988.
8.
MurrayCJLLopezAD, editors. The global burden of disease. Global Burden of Disease and Injury Series. Boston: The Harvard School of Public Health, 1996.
9.
American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care2002; 25(1): 213–229.
10.
LustmanPJ. Depression and poor glycemic control: A meta-analytic review of the literature. Diabetes Care2000; 23(7): 934–942.
11.
de GrootM., Association of depression and diabetes complications: A metaanalysis. Psychosomatic Medicine2001; 63(4): 619–630.
12.
McGillJB. Relationship of depression to compliance with self-monitoring of blood glucose. Diabetes1992; 41: A84.
13.
CiechanowskiPSKatonWJRussoJE. Depression and diabetes: Impact of depressive symptoms on adherence, function, and costs. Archives of Internal Medicine2000; 160(21): 3278–3285.
14.
GlasgowRE. Behavioral science in diabetes. Contributions and opportunities. Diabetes Care1999; 22(5): 832–843.
15.
JacobsonAM. Depression and diabetes. Diabetes Care1993; 16(12): 1621–1623.
16.
DrussBG. Mental health care quality under managed care in the United States: A view from the Health Employer Data and Information Set (HEDIS). American Journal of Psychiatry2002; 159(5): 860–862.
17.
EgedeLEZhengDSimpsonK. Comorbid depression is associated with increased health care use and expenditures in individuals with diabetes. Diabetes Care2002; 25(3): 464–470.
18.
GoldenSH. Depressive symptoms and the risk of type 2 diabetes. Diabetes Care2004; 27(2): 429–435.
19.
MusselmanDL. Relationship of depression to diabetes types 1 and 2: Epidemiology, biology, and treatment. Biological Psychiatry2003; 54(3): 317–329.
20.
CarneyC. Diabetes mellitus and major depressive disorder: An overview of prevalence, complications, and treatment. Depression & Anxiety1998; 7(4): 149–157.
21.
PadgettDK. Sociodemographic and disease-related correlates of depressive morbidity among diabetic patients in Zagreb, Croatia. Journal of Nervous & Mental Disease1993; 181(2): 123–129.
22.
DiMatteoMRLepperHSCroghanTW. Depression is a risk factor for noncompliance with medical treatment: Meta-analysis of the effects of anxiety and depression on patient adherence. Archives of Internal Medicine2000; 160: 2101–2107.
23.
MarcusMD. Lifetime prevalence of major depression and its effect on treatment outcome in obese type II diabetic patients. Diabetes Care1992; 15(2): 253–255.
GoldsteinDE. Tests of glycemia in diabetes. Diabetes Care1995; 18(6): 896–909.
26.
AdamsAS. Barriers to self-monitoring of blood glucose among adults with diabetes in an HMO. BMC Health Services Research2003; 3(6).
27.
SoumeraiSB. Effects of HMO coverage of self-monitoring devices on diabetes self-care and glycemic control. Archives of Internal Medicine2004; 164: 645–652.
28.
Von KorffMWagnerEHSaundersK. A chronic disease score from automated pharmacy data. Journal of Clinical Epidemiology1992; 45(2): 197–203.
29.
ClarkDO. A chronic disease score with empirically derived weights. Medical Care1995; 33(8): 783–795.
30.
Anonymous. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Archives of Internal Medicine1998; 158(17): 1855–1867.
31.
National Committee for Quality Assurance (NCQA). Antidepressant medication management (effective acute treatment phase): Percentage of members who remained on an antidepressant drug during the entire 84-day (12-week) acute treatment phase. In HEDIS 2004. Health plan employer data and information set. Volume 2, Technical specifications. Washington, DC: National Committee for Quality Assurance (NCQA), 2003.
32.
National Committee for Quality Assurance. Antidepressant medication management (effective continuation phase treatment); percentage of members who remained on an antidepressant drug for at least 180 days (six months). In HEDIS 2004. Health plan employer data and information set. Technical specifications. Washington, DC: National Commitee for Quality Assurance (NCQA), 2003.
33.
SingerJDWillettJB, Applied longitudinal data analysis: Modeling change and event occurrence. New York: Oxford University Press, 2003.
34.
LittellRC. SAS System for mixed models. Cary, NC: SAS Institute Inc., 1996.
35.
CulbertsonFM. Depression and gender. An international review. American Psychologist1997; 52(1): 25–31.
36.
PiccinelliMWilkinsonG. Gender differences in depression. Critical review. British Journal of Psychiatry2000; 177: 486–492.
37.
CarterJSPughJAMonterrosaA. Non-insulin-dependent diabetes mellitus in minorities in the United States. Annals of Internal Medicine1996; 125(3): 221–232.
38.
LustmanPJGriffithLSClouseRE. Depression in adults with diabetes. Results of 5-yr follow-up study. Diabetes Care1988; 11(8): 605–612.
39.
GoodnickPJ. Diabetes mellitus and depression: Issues in theory and treatment. Psychiatric Annals1997; 27(5): 353–359.
40.
de GrootM. Glycemic control and major depression in patients with type 1 and type 2 diabetes mellitus. Journal of Psychosomatic Research1999; 46(5): 425–435.
41.
Tellez-ZentenoJFCardielMH. Risk factors associated with depression in patients with type 2 diabetes mellitus. Archives of Medical Research2002; 33(1): 53–60.
42.
National Center for Quality Assurance. HEDIS 3.0, Effectiveness of care: Antidepressant medical management. Washington, DC, 1997.
ChinMHZhangJXMerrellK. Diabetes in the African-American Medicare population. Morbidity, quality of care, and resource utilization. Diabetes Care1998; 21(7): 1090–1095.
45.
FaasASchellevisFGvan EijkJT, The efficacy of self-monitoring of blood glucose in NIDDM subjects: A criteria-based literature review. Diabetes Care1997; 20(9): 1482–1486.
46.
FranciosiM. The impact of blood glucose self-monitoring on metabolic control and quality of life in type 2 diabetic patients: An urgent need for better educational strategies. Diabetes Care2001; 24(11): 1870–1877.
47.
KennedyL. Self-monitoring of blood glucose in type 2 diabetes: Time for evidence of efficacy. Diabetes Care2001; 24(6): 977–978.
48.
GoodallTAHalfordWK. Self-management of diabetes mellitus: A critical review. Health Psychology1991; 10(1): 1–8.
49.
KleinCE. Home blood glucose monitoring: Effectiveness in a general population of patients who have non-insulin-dependent diabetes mellitus. Journal of General Internal Medicine1993; 8(11): 597–601.
50.
OkiJCFloraDLIsleyWL. Frequency and impact of SMBG on glycemic control in patients with NIDDM in an urban teaching hospital clinic. Diabetes Educator1997; 23(4): 419–424.
51.
WysockiT. Impact of blood glucose monitoring on diabetic control: Obstacles and interventions. Journal of Behavioral Medicine1989; 12(2): 183–205.
